Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

BACKGROUND: The proteasome inhibitor bortezomib can inhibit activation of the transcription factor NF-κB, a mechanism implicated in its anti-neoplastic effects observed in mantle cell lymphoma (MCL). However, NF-κB can be activated through many distinct mechanisms, including proteasome independent p...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Yang, David T, Young, Ken H, Kahl, Brad S, Markovina, Stephanie, Miyamoto, Shigeki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2008
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2408930/
https://ncbi.nlm.nih.gov/pubmed/18489772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-7-40
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak